CLA – Conjugated Linoleic Acid 1250 mg — 90 Softgels — Supports Body Composition & Metabolic Function*
LifeSource Vitamins CLA provides 1,250 mg conjugated linoleic acid (from safflower oil) per softgel to support healthy body composition, fat metabolism, and lean mass retention when used with diet and exercise.* Produced in FDA-registered, GMP-certified facilities and
3rd-party lab tested for purity, potency & label accuracy.*
Research Promise:
At LifeSource Vitamins, our commitment is rooted in research and results. Every benefit below is supported by human clinical studies indexed in the National Institutes of Health (NIH) via PubMed, with full texts available in the National Library of Medicine (NLM) PubMed Central (PMC) when available. In addition, we reference reviews from 39 leading health organizations and insights from 20 top global universities to ensure our guidance aligns with credible science.*
Clinically Studied Benefits (with research)
• Supports modest reductions in body fat mass* — Meta-analysis of RCTs reports small but significant fat-mass loss with ~3.2 g/day CLA over ~6 months. (NIH/PubMed — Whigham LD, 2007)
• Helps improve body composition in some populations* — Trials note fat-mass reduction and lean-mass preservation under controlled conditions. (NIH/PubMed — Riserus U, 2001)
• Weight-maintenance support* — CLA supplementation helped limit seasonal or long-term fat gain in certain studies. (NIH/PubMed — Blankson H, 2000; NIH/PubMed — Gaullier JM, 2005)
• Lean-mass retention during weight programs* — Some trials found better fat-free mass preservation. (NIH/PubMed — Thom E, 2001)
• Abdominal fat outcomes* — 12-week RCT reported decreases in fat mass and waist-to-hip ratio. (NIH/PubMed — Chen SC, 2012)
• Hormonal marker changes* — CLA supplementation reduced circulating leptin in overweight adults. (NIH/PubMed — Steck S, 2007)
• Metabolic effects are mixed* — Some studies report changes in insulin sensitivity; findings vary by isomer and population. (NIH/PubMed — Riserus U, 2002) (NIH-indexed reviews)
• Overall tolerability in trials* — Review notes CLA generally well-tolerated across 6–12 months. (NIH/PubMed — 2012 Review) (NIH-indexed reviews)
Additional / Promising Evidence*
• Exercise synergy* — Training plus CLA has shown added body-composition benefits in some studies. (NIH/PubMed — Colakoglu M, 2006)
• Inflammatory marker modulation* — Trials report effects on CRP and cytokines (direction varies by isomer/dose). (NIH/PubMed — Moloney F, 2004) (NIH-indexed reviews)
• Oxidative-stress pathways (mechanistic)* — Reviews describe potential antioxidant signaling roles. (NIH/PubMed — 2010 Review) (NIH-indexed reviews)
• Immune-marker effects (overview)* — Evidence summaries describe CLA’s influence on immune responses. (NIH/PubMed — 2019 Review) (NIH-indexed reviews)
• Cardiometabolic endpoints (mixed)* — Studies report variable effects on lipids and insulin function. (NIH/PubMed — Raff M, 2008) (NIH-indexed reviews)
• Bone-related findings (preclinical/human exploratory)* — Early data suggest possible effects on bone markers. (NIH/PubMed — Watkins BA, 2009)
University / Academic Context*
• Isomer-specific outcomes* — t10,c12 vs c9,t11 CLA display different metabolic effects in academic reviews. (NIH-indexed reviews) (Evidence — Harvard, 2024)
• Dose & duration considerations* — Analyses discuss small effect sizes and need for ≥6 months for changes. (NIH/PubMed — Whigham LD, 2007)
• Lean-mass vs fat-mass tradeoffs* — University-affiliated trials report context-dependent results. (NIH/PubMed — Riserus U, 2001)
Global Evidence & Authoritative Reviews*
• Systematic reviews & guidance — Summaries note small average effects on fat mass with mixed metabolic findings; emphasize lifestyle pairing. (NIH/PubMed — 2012 Review) (NIH-indexed reviews)
• Clinical context — Evidence reviews from university nutrition programs and public health groups recommend prudent use and monitoring. (Evidence — Cochrane/Academic, 2012–2020)
We monitor research from leading institutions — Harvard, Johns Hopkins, Mayo Clinic, Cleveland Clinic, Cambridge, Oxford, Stanford, Yale, Tufts, University of Florida, Oregon State University – Linus Pauling Institute, Columbia, Cornell, and Ohio State — to keep our guidance aligned with credible science.*
Brief Benefit Bullets
• Supports modest fat-mass reduction when paired with diet & exercise*
• Helps retain lean mass during weight programs*
• Promotes fat oxidation and body-composition goals*
• Evidence varies by isomer, dose, and duration*
3rd-party tested for purity & potency
Suggested Use
See product label for full directions, or as directed by your healthcare professional. If pregnant, nursing, taking medications, or have a medical condition, consult your physician.* Keep out of reach of children.
Product Specifications
• Serving Size — 1 Softgel Capsule
• Servings Per Container — 90
• Conjugated Linoleic Acid (from Safflower Oil) — 1,250 mg per serving
• Total Active CLA (C18:2 conjugated) — 1,000 mg per serving
• Other Fatty Acids — 185 mg per serving
• Calories/Total Fat — 15 kcal / 1.5 g
• Other Ingredients — Softgel (gelatin, glycerin, water)
• Free From — No sugar, salt, dairy, yeast, wheat, gluten, corn, soy, preservatives, artificial colors or flavors*
• Quality — Third-party tested for identity, potency & purity
LifeSource Vitamins — Proudly American — Since 1992
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
CLA 1250 — 90 softgels — supports body composition, fat metabolism & lean-mass retention when paired with diet/exercise; label-verified actives, 3rd-party tested. Clinically Studied Ingredients — NIH/PubMed!*
